Evidence map›Paper›PMID 35572584›Full record

ArticleFrontiers in immunology2022

Editorial: Advances in T Cell Therapeutic Vaccines for HIV.

Bernard J C Macatangay, Alan L Landay, Felipe Garcia, Charles R Rinaldo

Abstract readEditorial
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Bernard J C MacatangayDepartment of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.
Alan L LandayDepartment of Internal Medicine, Rush Medical College, Chicago, IL, United States.
Felipe GarciaInfectious Diseases Department, Hospital Clinic Barcelona, Barcelona, Spain.
Charles R RinaldoDepartment of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.

Funding

Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
Comparison of Dendritic Cell-Based Therapeutic Vaccine Strategies for HIV Functional CureU01AI131285 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MACATANGAY, BERNARD JONAS C, MELLORS, JOHN W · 2017 to 2021
$7.4M
NIAID NIH HHS U01 AI131285NIAID NIH HHS UM1 AI106701
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AIDS VaccinesHIV-1HIV InfectionsHumansT-LymphocytesAIDS VaccinesHIVHIV remissionimmunotherapyT celltherapeutic vaccine

Identifiers

PMID35572584
PMCPMC9094404

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.